Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:PARNFNASDAQ:PHIONASDAQ:RTTROTCMKTS:WIZP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePARNFParnell Pharmaceuticals$0.08$0.08$0.05▼$0.35N/A25.25N/AN/APHIOPhio Pharmaceuticals$2.43-1.9%$2.12$0.97▼$9.79$11.52M0.912.46 million shs84,045 shsRTTRRitter Pharmaceuticals$3.16-3.2%$2.99$0.15▼$1.27$145.84M-0.4314.23 million shs4,783 shsWIZPMawson Infrastructure Group$0.50+5.2%$0.55$0.07▼$1.45$466.87M1.77141,517 shs366,575 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePARNFParnell Pharmaceuticals0.00%0.00%0.00%0.00%+79,900.00%PHIOPhio Pharmaceuticals0.00%+12.17%-1.06%+127.48%-53.44%RTTRRitter Pharmaceuticals0.00%-10.99%-20.67%-4.53%+1,808.21%WIZPMawson Infrastructure Group+13.15%+28.18%-22.17%+21.71%-67.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPARNFParnell PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APHIOPhio Pharmaceuticals2.1947 of 5 stars3.52.00.00.00.62.50.6RTTRRitter PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePARNFParnell Pharmaceuticals 0.00N/AN/AN/APHIOPhio Pharmaceuticals 3.00Buy$14.00475.18% UpsideRTTRRitter Pharmaceuticals 0.00N/AN/AN/AWIZPMawson Infrastructure Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PHIO, RTTR, PARNF, and WIZP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.006/5/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.004/8/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPARNFParnell PharmaceuticalsN/AN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/A$0.69 per shareN/ARTTRRitter PharmaceuticalsN/AN/AN/AN/A$0.10 per shareN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/A$0.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePARNFParnell PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/APHIOPhio Pharmaceuticals-$7.15M-$6.42N/A0.65N/AN/A-105.65%-89.19%8/13/2025 (Estimated)RTTRRitter Pharmaceuticals-$10.13MN/AN/A∞N/AN/AN/A-162.05%N/AWIZPMawson Infrastructure Group-$3.45M-$0.33N/AN/AN/AN/AN/A-85.32%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPARNFParnell PharmaceuticalsN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ARTTRRitter PharmaceuticalsN/AN/AN/AN/AN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPARNFParnell PharmaceuticalsN/AN/AN/APHIOPhio PharmaceuticalsN/A10.5810.58RTTRRitter PharmaceuticalsN/A3.673.67WIZPMawson Infrastructure GroupN/A1.131.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPARNFParnell PharmaceuticalsN/APHIOPhio Pharmaceuticals57.31%RTTRRitter Pharmaceuticals0.84%WIZPMawson Infrastructure GroupN/AInsider OwnershipCompanyInsider OwnershipPARNFParnell PharmaceuticalsN/APHIOPhio Pharmaceuticals0.59%RTTRRitter Pharmaceuticals15.40%WIZPMawson Infrastructure GroupN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePARNFParnell Pharmaceuticals51N/AN/ANot OptionablePHIOPhio Pharmaceuticals104.80 million4.77 millionNot OptionableRTTRRitter Pharmaceuticals746.15 millionN/ANot OptionableWIZPMawson Infrastructure Group2486.32 millionN/ANot OptionablePHIO, RTTR, PARNF, and WIZP HeadlinesRecent News About These CompaniesMawson Infrastructure Group (OTCMKTS:WIZP) Stock Price Down 0.2% - Should You Sell?June 18, 2025 | marketbeat.comH.C. Wainwright Sticks to Their Hold Rating for Mawson Infrastructure Group (MIGI)April 2, 2025 | markets.businessinsider.comMawson Infrastructure releases 2025 company presentationJanuary 28, 2025 | markets.businessinsider.comMawson Infrastructure names William Regan as CFOJanuary 17, 2025 | markets.businessinsider.comMawson Infrastructure reports December revenue $5.26M, up 7% month/monthJanuary 14, 2025 | markets.businessinsider.comMawson Infrastructure executes new customer agreementJanuary 7, 2025 | markets.businessinsider.comMawson Infrastructure Group Inc (MIGI) Stock Trading RecapDecember 10, 2024 | bovnews.comBCreditors file Chapter 11 involuntary petition against Mawson Infrastructure, latter vows to 'vigorously defend' itselfDecember 6, 2024 | bizjournals.comWhy Is Mawson Infrastructure Group Inc (MIGI) Stock Lagging Behind -56.76% from Its 50-Day SMA?December 6, 2024 | bovnews.comBMawson Infrastructure reports August revenue $4.44M; digital colocation business up 166% Y/YSeptember 16, 2024 | seekingalpha.comMawson Infrastructure Group Inc (MIGI) Stock: More Strategic Than Meets the EyeAugust 24, 2024 | bovnews.comBMawson Infra Gr (NASDAQ:MIGI) Stock, Short Interest ReportAugust 14, 2024 | benzinga.comMawson Infrastructure Group adds new customer at Midland bitcoin facilityDecember 20, 2023 | bizjournals.comMawson announces agreement for half of Midland bitcoin facility capacityOctober 19, 2023 | bizjournals.comMawson Infrastructure reports BTC production of 69 in July, down 3% M/MAugust 24, 2023 | seekingalpha.comH.C. Wainwright Sticks to Its Buy Rating for Mawson Infrastructure Group (MIGI)August 24, 2023 | markets.businessinsider.comMawson Infrastructure Group Inc. Invites Submission of Indication of Interest for its BTC Hosting and HPC Co-location ServicesJuly 25, 2023 | technews.tmcnet.comTMawson Infrastructure Group Inc. Announces Monthly Operational Update for June 2023July 19, 2023 | businesswire.comMawson Infrastructure Group Inc. Announces Monthly Operational Update for May 2023June 14, 2023 | technews.tmcnet.comTMawson Infrastructure Group names new president, CEOMay 22, 2023 | bizjournals.comWith Significant Increases In Megawatt Capacity And Bitcoin Production, Mawson Infrastructure Group (NASDAQ: MIGI) May Attract More Bitcoin Mining InvestorsApril 11, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHIO, RTTR, PARNF, and WIZP Company DescriptionsParnell Pharmaceuticals OTCMKTS:PARNF$0.08 0.00 (0.00%) As of 04/22/2025Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for enhancing cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product for the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also offers mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.Phio Pharmaceuticals NASDAQ:PHIO$2.43 -0.05 (-1.85%) As of 07/3/2025 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.Ritter Pharmaceuticals NASDAQ:RTTRRitter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.Mawson Infrastructure Group OTCMKTS:WIZP$0.50 +0.02 (+5.19%) As of 07/3/2025Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company is headquartered in North Sydney, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
